BACKGROUND: Drug-eluting stents successfully reduce restenosis at the cost of delayed re-endothelialization. A novel concept to enhance re-endothelialization is the use of antibody-coated stents which capture circulating progenitor cells. A CD34-positive-cell-capturing stent was recently developed with conflicting clinical results. CD133 is a glycoprotein expressed on circulating hematopoietic and putative endothelial-regenerating cells and may be superior to CD34. OBJECTIVE: The aim of our study was to develop a CD133-cell-capturing bare-metal stent and investigate feasibility, safety, and efficacy of CD133-stents in terms of re-endothelialization and neointima inhibition. METHODS AND RESULTS: Anti-human CD133-antibodies were covalently attached to bare-metal stents. In vitro, binding capacity of CD133-stents was studied, revealing a significantly higher affinity of human CD133-positive cells to CD133-stents compared with mononuclear cells (MNCs). In vivo, 15 landrace pigs received BMS and CD133-stents in either RCX or LAD (n = 30 stents). Re-endothelialization was examined on day 1 (n = 4), 3 (n = 4) and day 7 (n = 4) using scanning electron microscopy. In histology, injury and inflammatory scores, as well as diameter restenosis were evaluated after day 7 (n = 3), 14 (n = 4), and 28 (n = 2). Overall no reduction in re-endothelialization, diameter stenosis or inflammatory score was seen with CD133-stents. CONCLUSION: Stent coating with anti-human CD133-antibodies was successfully achieved with effective binding of CD133-positive cells. However, in vivo, no difference in re-endothelialization or neointima formation was evident with the use of CD133-stents compared with BMS. The low number of circulating CD133-positive cells and an increase in unspecific binding of MNCs over time may account for the observed lack of efficacy.
BACKGROUND: Drug-eluting stents successfully reduce restenosis at the cost of delayed re-endothelialization. A novel concept to enhance re-endothelialization is the use of antibody-coated stents which capture circulating progenitor cells. A CD34-positive-cell-capturing stent was recently developed with conflicting clinical results. CD133 is a glycoprotein expressed on circulating hematopoietic and putative endothelial-regenerating cells and may be superior to CD34. OBJECTIVE: The aim of our study was to develop a CD133-cell-capturing bare-metal stent and investigate feasibility, safety, and efficacy of CD133-stents in terms of re-endothelialization and neointima inhibition. METHODS AND RESULTS: Anti-humanCD133-antibodies were covalently attached to bare-metal stents. In vitro, binding capacity of CD133-stents was studied, revealing a significantly higher affinity of humanCD133-positive cells to CD133-stents compared with mononuclear cells (MNCs). In vivo, 15 landrace pigs received BMS and CD133-stents in either RCX or LAD (n = 30 stents). Re-endothelialization was examined on day 1 (n = 4), 3 (n = 4) and day 7 (n = 4) using scanning electron microscopy. In histology, injury and inflammatory scores, as well as diameter restenosis were evaluated after day 7 (n = 3), 14 (n = 4), and 28 (n = 2). Overall no reduction in re-endothelialization, diameter stenosis or inflammatory score was seen with CD133-stents. CONCLUSION: Stent coating with anti-humanCD133-antibodies was successfully achieved with effective binding of CD133-positive cells. However, in vivo, no difference in re-endothelialization or neointima formation was evident with the use of CD133-stents compared with BMS. The low number of circulating CD133-positive cells and an increase in unspecific binding of MNCs over time may account for the observed lack of efficacy.
Authors: Mette K Hagensen; Merete K Raarup; Martin B Mortensen; Troels Thim; Jens R Nyengaard; Erling Falk; Jacob F Bentzon Journal: Cardiovasc Res Date: 2011-10-19 Impact factor: 10.787
Authors: Ramiro Flores-Ramírez; Artemio Uribe-Longoria; María M Rangel-Fuentes; Pedro Gutiérrez-Fajardo; Rosario Salazar-Riojas; Daniel Cervantes-García; José H Treviño-Ortiz; Genoveva J Benavides-Chereti; Luciana P Espinosa-Oliveros; Ramón H Limón-Rodríguez; Rogelio Monreal-Puente; Juan L González-Treviño; Augusto Rojas-Martínez Journal: Cardiovasc Revasc Med Date: 2010 Apr-Jun
Authors: M Peichev; A J Naiyer; D Pereira; Z Zhu; W J Lane; M Williams; M C Oz; D J Hicklin; L Witte; M A Moore; S Rafii Journal: Blood Date: 2000-02-01 Impact factor: 22.113
Authors: U M Gehling; S Ergün; U Schumacher; C Wagener; K Pantel; M Otte; G Schuch; P Schafhausen; T Mende; N Kilic; K Kluge; B Schäfer; D K Hossfeld; W Fiedler Journal: Blood Date: 2000-05-15 Impact factor: 22.113
Authors: Gaku Nakazawa; Juan F Granada; Carlos L Alviar; Armando Tellez; Greg L Kaluza; Margaret Yoklavich Guilhermier; Sherry Parker; Stephen M Rowland; Frank D Kolodgie; Martin B Leon; Renu Virmani Journal: JACC Cardiovasc Interv Date: 2010-01 Impact factor: 11.195
Authors: Marco L Rossi; Dennis Zavalloni; Gabriele L Gasparini; Ruggiero Mango; Guido Belli; Patrizia Presbitero Journal: Int J Cardiol Date: 2009-01-09 Impact factor: 4.164
Authors: Francesco Pelliccia; Marco Zimarino; Giuseppe De Luca; Nicola Viceconte; Gaetano Tanzilli; Raffaele De Caterina Journal: Stem Cells Transl Med Date: 2022-05-27 Impact factor: 7.655